Treats hypertension. ANDA 91163, held by Aurobindo Pharma Ltd. Fosinopril Sodium.
As of Nov 16, 2026, ANDA 91163 (Fosinopril Sodium), held by Aurobindo Pharma Ltd, was first approved by FDA on Mar 30, 2011, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Fosinopril sodium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. Fosinopril sodium tablets are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics with or without digitalis (see DOSAGE AND ADMINISTRATION ). In using fosinopril sodium tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 30, 2011 | Original application | Approved | None posted |
| Fosinopril Sodium10MG · tablet;oral | Fosinopril Sodium | Rx |
| Fosinopril Sodium20MG · tablet;oral | Fosinopril Sodium | Rx |
| Fosinopril Sodium40MG · tablet;oral | Fosinopril Sodium | Rx |
| Dec 31, 2013 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 30, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters